Trials / Terminated
TerminatedNCT04012099
the Hypertrophic Scar Prevention of BMT101.
An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of BMT 101 Administration for the Prevention of Hypertrophic Scar
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Hugel · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
An Independent Evaluator-Blind, Dose-Escalation, Untreated-Controlled, Within-Subject, Phase 2a Therapeutic Exploratory Clinical Trial
Detailed description
As a comparative evaluation between the control group (untreated-control) and the study group (treatment) within a subject, it was decided to assign ten subjects to each of the three dose groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMT101 | Intradermal injection to each of 3 dose-groups. |
Timeline
- Start date
- 2019-08-21
- Primary completion
- 2023-05-10
- Completion
- 2023-05-10
- First posted
- 2019-07-09
- Last updated
- 2023-05-24
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04012099. Inclusion in this directory is not an endorsement.